Table 4 Results of treatment discontinuations across randomised controlled trials
Intervention | Study | N | Treatment discontinuation, n (%) | Most common AEs leading to discontinuations | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Â | Â | Â | All | Due to AE | Due to death | Due to PD | Due to lost to follow-up | Due to patient decision | Due to other reasons | Â |
Pazopanib | PALETTE study 2011/2 | 246 | 240 (97.6) | 41 (16.7) | 3 (1.2) | 178 (72.4) | 0 (0.0) | 14 (5.7) | 4 (1.6)¶ | ALT elevation, dyspnoea, left ventricular dysfunction, fatigue, hypertension, vomiting, depressed mood, embolism, nausea, pericardial effusion, and small intestinal obstruction |
Placebo | PALETTE study 2011/2 | 123 | 123 (100) | 3 (2.4) | 0 (0) | 119 (96.7) | 0 (0.0) | 1 (0.8) | 0 (0.0) | Dyspnoea |
Trabectedin 1.5 mg/m2 q3w | Demetri 2009 | 136 | 128 (94.1) | 12 (8.8) | 2 (1.5) | 89 (65.4) | 2 (1.5) | 17 (12.5) | 6 (4.4)†| AEs leading to disconsolation were not reported |
Trabectedin 0.58 mg/m2 qw | Demetri 2009 | 134 | 134 (100) | 10 (7.5) | 3 (2.2) | 94 (70.1) | 0 (0.0) | 6 (4.5) | 21 (15.7)‡ | AEs leading to disconsolation were not reported |
Dacarbazine | GEIS study 2011 | 54 | 50 (92.6) | 2 (3.7) | - | 41 (75.9) | 0 (0.0) | - | 7 (13.0) | - |
Gemcitabine + Dacarbazine | GEIS study 2011 | 59 | 47 (79.7) | 0 (0.0) | - | 36 (61.0) | 0 (0.0) | 1 (1.7) | 10 (16.9) | - |
Gemcitabine | Pautier 2009 | 84* | - | 3 | - | - | - | - | - | AEs leading to disconsolation were not reported |
Gemcitabine + Docetaxel | Pautier 2009 | Â | - | 9 | - | - | - | - | - | Hypersensitivity in one patient |